MYMD
Income statement / Annual
Last year (2023), MyMD Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, MyMD Pharmaceuticals, Inc.'s net income was -$4.00 M.
See MyMD Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.58 M |
$1.67 M |
$3.93 M |
$2.96 M |
$2.12 M |
$4.43 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$29.45 K
|
$74.06 K
|
$1.54 M
|
$1.42 M
|
$1.08 M
|
$950.79 K
|
$1.18 M
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$29.45 K
|
$1.50 M
|
$127.29 K
|
$2.51 M
|
$1.88 M
|
$1.16 M
|
$3.25 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.95
|
0.08
|
0.64
|
0.63
|
0.55
|
0.73
|
| Research and Development Expenses |
$7.87 M
|
$9.07 M
|
$6.75 M
|
$2.47 M
|
$3.63 M
|
$1.06 M
|
$1.26 M
|
$1.19 M
|
$1.41 M
|
$916.31 K
|
| General & Administrative Expenses |
$5.44 M
|
$6.22 M
|
$6.42 M
|
$5.81 M
|
$5.77 M
|
$5.67 M
|
$4.08 M
|
$3.01 M
|
$4.03 M
|
$3.98 M
|
| Selling & Marketing Expenses |
$8.49 M
|
$0.00
|
$0.00
|
$22.96 K
|
$238.04 K
|
$1.78 M
|
$1.85 M
|
$2.14 M
|
$2.54 M
|
$1.30 M
|
| Selling, General & Administrative Expenses |
$8.49 M
|
$6.22 M
|
$21.46 M
|
$5.81 M
|
$3.32 M
|
$7.45 M
|
$6.13 M
|
$5.15 M
|
$6.57 M
|
$5.28 M
|
| Other Expenses |
-$763.00 K
|
$0.00
|
$0.00
|
$18.33 K
|
$40.01 K
|
$171.11 K
|
$171.11 K
|
$171.11 K
|
$236.71 K
|
$258.57 K
|
| Operating Expenses |
$17.12 M
|
$15.28 M
|
$6.75 M
|
$8.30 M
|
$3.32 M
|
$8.68 M
|
$7.56 M
|
$6.51 M
|
$8.22 M
|
$6.46 M
|
| Cost And Expenses |
$17.12 M
|
$15.28 M
|
$28.20 M
|
$8.30 M
|
$3.40 M
|
$10.22 M
|
$8.98 M
|
$7.59 M
|
$9.17 M
|
$7.63 M
|
| Interest Income |
$0.00
|
$83.99 K
|
$8.91 K
|
$141.00
|
$101.48 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$608.46 K
|
$1.19 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$16.36 M
|
$83.99 K
|
$617.37 K
|
$18.33 K
|
$74.06 K
|
$234.49 K
|
$249.89 K
|
$286.16 K
|
$300.00 K
|
$349.40 K
|
| EBITDA |
-$17.12 M |
$85.43 K |
-$28.81 M |
-$8.28 M |
-$3.95 M |
-$10.06 M |
-$5.05 M |
$0.00 |
-$9.68 M |
-$2.78 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-2.5
|
-6.04
|
-1.29
|
0
|
-4.58
|
-0.63
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-2.15
|
-6.04
|
-1.29
|
-1.12
|
-4.58
|
-0.72
|
| Total Other Income/Expenses Net |
$13.12 M
|
$85.43 K
|
-$1.08 M
|
$133.49 K
|
$57.83 K
|
-$789.00 K
|
-$753.00 K
|
$25.10 K
|
$100.97 K
|
$76.95 K
|
| Income Before Tax |
-$4.00 M
|
-$15.20 M
|
-$29.89 M
|
-$9.49 M
|
-$3.89 M
|
-$10.85 M
|
-$5.81 M
|
-$3.30 M
|
-$9.58 M
|
-$3.13 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-2.47
|
-6.51
|
-1.48
|
-1.12
|
-4.53
|
-0.71
|
| Income Tax Expense |
$4.22 M
|
-$85.43 K
|
-$8.91 K
|
$1.19 M
|
-$83.65 K
|
-$2.29 M
|
-$753.00 K
|
$1.33 M
|
-$269.00 K
|
$15.79 K
|
| Net Income |
-$4.00 M
|
-$15.20 M
|
-$29.89 M
|
-$10.68 M
|
-$3.89 M
|
-$10.85 M
|
-$5.81 M
|
-$3.30 M
|
-$9.31 M
|
-$3.13 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-2.47
|
-6.51
|
-1.48
|
-1.12
|
-4.4
|
-0.71
|
| EPS |
-2.59 |
-11.68 |
-25.6 |
-90.86 |
-380.79 |
-23.73 |
-117.39 |
-116.81 |
-347.78 |
-126.52 |
| EPS Diluted |
-2.59 |
-11.68 |
-25.6 |
-90.86 |
-380.79 |
-23.73 |
-117.39 |
-116.81 |
-347.78 |
-126.52 |
| Weighted Average Shares Out |
$1.54 M
|
$38.83 M
|
$35.02 M
|
$939.00 K
|
$10.21 K
|
$457.25 K
|
$49.45 K
|
$28.28 K
|
$26.78 K
|
$24.72 K
|
| Weighted Average Shares Out Diluted |
$1.54 M
|
$38.83 M
|
$35.02 M
|
$939.61 K
|
$10.21 K
|
$457.25 K
|
$49.45 K
|
$28.28 K
|
$26.78 K
|
$24.72 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
